Belgium· BE-AMP-SAM561555-00
Aimovig 140 mg
A erenumab product containing erenumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Erenumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Erenumab · ATC N02CD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Erenumab
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- N02CD01
- ATC class
- Erenumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb7730450
- be_apb3954039EUR 470.47
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Erenumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAIMOVIGNovartis Europharm Limited, Dublin
- SpainAIMOVIG 140 MG SOLUCIÓN INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- IcelandAimovigNovartis Europharm Limited*
- SwedenAimovig 140 mg Injektionsvätska, lösning i förfylld injektionspennaNovartis Europharm Limited
- United KingdomAimovig 140mg/1ml solution for injection pre-filled pensNovartis Pharmaceuticals UK Ltd
- United StatesAIMOVIGAmgen, Inc
- FinlandAimovigNovartis Europharm Limited
- NetherlandsAimovig 140 mg oplossing voor injectie in voorgevulde penNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aimovig
- Liechtenstein · Aimovig
- Norway · Aimovig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd44b1ab-2a39-4032-9594-7d98516b894d GET /v1/drugs/dd44b1ab-2a39-4032-9594-7d98516b894d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Aimovig 140 mg",
"name_fr": "Aimovig 140 mg",
"name_nl": "Aimovig 140 mg",
"amp_code": "SAM561555-00",
"strengths": [
"140.0000"
],
"pack_count": 4,
"substances": [
"Erenumab",
"Sodium Hydroxide",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Erenumab",
"authorisation_numbers": [
"EU/1/18/1293/004",
"EU/1/18/1293/005"
]
}See everything about erenumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.